Search Results - "PROPPER, David J"

Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer by Kocher, Hemant M., Basu, Bristi, Froeling, Fieke E. M., Sarker, Debashis, Slater, Sarah, Carlin, Dominic, deSouza, Nandita M., De Paepe, Katja N., Goulart, Michelle R., Hughes, Christine, Imrali, Ahmet, Roberts, Rhiannon, Pawula, Maria, Houghton, Richard, Lawrence, Cheryl, Yogeswaran, Yathushan, Mousa, Kelly, Coetzee, Carike, Sasieni, Peter, Prendergast, Aaron, Propper, David J.

“…Pre-clinical models have shown that targeting pancreatic stellate cells with all-trans-retinoic-acid (ATRA) reprograms pancreatic stroma to suppress pancreatic…”
Get full text

Harnessing cytokines and chemokines for cancer therapy by Propper, David J., Balkwill, Frances R.

“…During the past 40 years, cytokines and cytokine receptors have been extensively investigated as either cancer targets or cancer treatments. A strong…”
Get full text

Low-Dose IFN-γ Induces Tumor MHC Expression in Metastatic Malignant Melanoma by PROPPER, David J, CHAO, David, HARRIS, Adrian L, GANESAN, Trivadi S, BRAYBROOKE, Jeremy P, BAHL, Pru, THAVASU, Parames, BALKWILL, Frances, TURLEY, Helen, DOBBS, Nicola, GATTER, Kevin, TALBOT, Denis C

“…Specific antitumor immune responses require expression of MHC class I or II molecules on tumor cells, and MHC antigen down-regulation is a presumed tumor…”
Get full text

Phase I and Pharmacological Study of the Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A), in Patients with Advanced Solid Cancer by LEVITT, Nicola C, ESKENS, Ferry A. L. M, NAKAJIMA, Motowo, TALBOT, Denis C, STEWARD, William P, HARRIS, Adrian L, VERWEIJ, Jaap, O'BYRNE, Ken J, PROPPER, David J, DENIS, Louis J, OWEN, Samantha J, CHOI, Les, FOEKENS, John A, WILNER, Sue, WOOD, Jeanette M

“…This Phase I study of MMI270, an p.o. administered matrix metalloproteinase inhibitor, assessed toxicity, pharmacokinetics, and tumor response data and…”
Get full text

PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer by Propper, David J., Gao, Fangfei, Saunders, Mark P., Sarker, Debashis, Hartley, John A., Spanswick, Victoria J., Lowe, Helen L., Hackett, Louise D., Ng, Tony T., Barber, Paul R., Weitsman, Gregory E., Pearce, Sarah, White, Laura, Lopes, Andre, Forsyth, Sharon, Hochhauser, Daniel

“…Background Epidermal growth factor receptor (EGFR) is a therapeutic target to which HER2/HER3 activation may contribute resistance. This Phase I/II study…”
Get full text

A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis by BRAYBROOKE, Jeremy P, O'BYRNE, Kenneth J, SMITH, Kenneth, STEPHENS, Ross, GANESAN, Trivadi S, TALBOT, Denis C, HARRIS, Adrian L, PROPPER, David J, BLANN, Andrew, SAUNDERS, Mark, DOBBS, Nicola, HAN, Cheng, WOODHULL, Jane, MITCHELL, Karen, CREW, Jeremy

“…Renal cell carcinoma (RCC) is an angiogenic tumor resistant to standard cytotoxic chemotherapeutic agents. Although often responsive to immunomodulatory agents…”
Get full text

STARPAC clinical trial by Kocher, Hemant M., Basu, Bristi, Froeling, Fieke EM, Sarker, Debashis, Slater, Sarah, Carlin, Dominic, deSouza, Nandita M., De Paepe, Katja N., Goulart, Michelle R., Hughes, Christine, Imrali, Ahmet, Roberts, Rhiannon, Pawula, Maria, Houghton, Richard, Lawrence, Cheryl, Yogeswaran, Yathushan, Mousa, Kelly, Coetzee, Carike, Sasieni, Peter, Prendergast, Aaron, Propper, David J.

Get full text

STAR_PAC: A Phase 1B study repurposing ATRA as stromal targeting agent along with gemcitabine and nab¬Paclitaxel for pancreatic cancer by Kocher, Hemant, Propper, David J, Alabaf, Sara, Mousa, Kelly, North, Bernard, Papoutsaki, Vasia, Smith, Donna-Michele, Ambily, Archana, Froeling, Fieke, Basu, Bristi, Gillmore, Roopinder, Davidson, Brian, Sarker, Debashis, Jodrell, Duncan, DeSouza, Nandita, Sasieni, Peter

“…Resume: My research directions include investigating the role of cytoskeletal proteins in pancreatic cancer progression, invasion and metastasis; investigating…”
Get full text

Phase I Study of the Novel Cyclic AMP (cAMP) Analogue 8-Chloro-cAMP in Patients with Cancer: Toxicity, Hormonal, and Immunological Effects by PROPPER, D. J, SAUNDERS, M. P, HARRIS, A. L, SALISBURY, A. J, LONG, L, O'BYRNE, K. J, BRAYBROOKE, J. P, DOWSETT, M, TAYLOR, M, TALBOT, D. C, GANESAN, T. S

“…The cyclic AMP (cAMP)-dependent protein kinase regulatory subunit RI is overexpressed in cancer cells. 8-Chloro-cAMP (8-Cl-cAMP) is an RII site-specific…”
Get full text

The in vitro effects of CRE‐decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines by Liu, Wai M., Scott, Katherine A., Shahin, Sipra, Propper, David J.

“…The cAMP response element consensus sequence directs the transcription of a wide range of genes. A 24‐mer single‐stranded cAMP response element decoy…”
Get full text

s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line by Liu, Wai M, Strauss, Sandra J, Chaplin, Tracy, Shahin, Sipra, Propper, David J, Young, Bryan D, Joel, Simon P, Malpas, James S

“…s-Thalidomide has proven efficacy in multiple myeloma. Although it has both antiangiogenic and pro-apoptotic effects, its primary mode of therapeutic action…”
Get more information

Functional PET imaging in cancer drug development by Avril, Norbert, Propper, David

“…New surrogate end points for monitoring response to cancer treatment are needed for both current and novel therapeutic strategies. Positron emission tomography…”
Get more information

Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen by BRAYBROOKE, J. P, HOULBROOK, S, CRAWLEY, J. E, PROPPER, D. J, O'BYRNE, K. J, STRATFORD, I. J, HARRIS, A. L, SHUKER, D. E. G, TALBOT, D. C

“…To develop, using dacarbazine as a model, reliable techniques for measuring DNA damage and repair as pharmacodynamic endpoints for patients receiving…”
Get full text

The effects of rapamycin on humoral immunity in vivo. Suppression of primary responses but not of ongoing alloantibody synthesis or memory responses by Propper, D J, Woo, J, Macleod, A M, Catto, G R, Thomson, A W

“…The effect of rapamycin on primary and secondary alloantibody responses to major histocompatibility complex class I antigens was investigated in inbred rat…”
Get more information

FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions by Propper, D J, Woo, J, Thomson, A W, Catto, G R, Macleod, A M

“…The influence of FK506 on in vivo alloantibody responses to major histocompatability class 1 antigens was investigated in inbred rat strains, and compared with…”
Get more information

Comparative effects of rapamycin, FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat by Thomson, A W, Propper, D J, Woo, J, Whiting, P H, Milton, J I, Macleod, A M

“…The immunosuppressive activity and comparative efficacy of rapamycin (RAPA), FK 506 and cyclosporine A (CsA) were investigated in rats following immunization…”
Get more information